Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 06, 2023, titled "Zydus receives final approval from the USFDA for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL), Single-Dose Vial".
Press Release Oct 06 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Sugammadex Injection in two dosage forms. This injection is used to reverse neuromuscular blockade during surgery and will be manufactured at their facility in Jarod, India. The press release highlights that the product had significant annual sales in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 29 2023
- Press Release Sep 20 2023
- Press Release Sep 19 2023
- Press Release Sep 15 2023
- Press Release Sep 13 2023
Later from Zydus Lifesciences
- Press Release Oct 16 2023
- Press Release Oct 20 2023
- Press Release Oct 25 2023
- Press Release Oct 30 2023
- Press Release Oct 31 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences